Preventing NASH with Empagliflozin and Linagliptin: A Diabetic Drug Combination
DOI:
https://doi.org/10.51985/JBUMDC2023227Keywords:
Anti-diabetic drugs, Non-alcoholic fatty liver disease, Non-alcoholic steatohepatitis.Abstract
Objective: To determine the effect of anti-diabetic drug combination of 25mg empagliflozin and 5mg linagliptin for the prevention of NASH.
Study Design & Setting: Quasi-Experimental Study design, Department of Gastroenterology, Medicare Cardiac and General Hospital Karachi from October 2022 to March 2023.
Methodology: This study was carried out after approval from the ethical board of the hospital. The selection criteria of patients included positive family history of obesity, hyperlipidemia/ hypertriglyceridemia, hypothyroidism, smoking and F3 Fibrosis on transient elastography. The initial screening of clinical history, physical examination, laboratory findings were recorded after taking the written consent from each patient. The baseline findings were recorded and the effect of drugs was examined after follow-up of six months.
Results: The study included 150 patients who received the treatment of empagliflozin and linagliptin. The mean age of these patients was 37±4.9 years. Majority of them were males 76% and 60% were diagnosed type 2 diabetes more than 5 years ago. Hyperglycemia and hypoglycemia were found in 16.7% in patients with headache of 26.7%. The baseline findings were significantly changed with effective and favorable results as p-value<0.001.
Conclusion: The treatment with combine effect of the antidiabetic drugs empagliflozin (25 mg) and linagliptin (5 mg) showed a safety profile of preventing NASH with the fixed dose. It reduced the ALT and AST levels, reduced BMI, triglyceride level, HBA1C and the risk of progression of advance liver disease NASH. After taking antidiabetic drugs, Fibrosis was improved and it showed F1–F2 on transient elastography.
References
Dufour J-F, Scherer R, Balp M-M, McKenna SJ, Janssens
N, Lopez P, et al. The global epidemiology of nonalcoholic
steatohepatitis (NASH) and associated risk factors–A targeted
literature review. Endocrine and Metabolic Science.
;3:100089.
Povsic M, Wong OY, Perry R, Bottomley J. A structured
literature review of the epidemiology and disease burden of
non-alcoholic steatohepatitis (NASH). Advances in therapy.
;36:1574-94.
Program TNE. How prevalent is NASH? 2019. Available
from: https://www.the-nash-education-program.com/whatis-nash/how-prevalent-is-nash/.
Aldossari KK. The epidemiology and characteristics of patients
with diabetes with or without NASH: a systematic review.
African Health Sciences. 2023;23(2):509-18.
Williams CD, Stengel J, Asike MI, Torres DM, Shaw J,
Contreras M, et al. Prevalence of nonalcoholic fatty liver
disease and nonalcoholic steatohepatitis among a largely
middle-aged population utilizing ultrasound and liver biopsy:
a prospective study. 2011;140(1):124-31.
Gastaldelli A, Cusi K. From NASH to diabetes and from
diabetes to NASH: mechanisms and treatment options. JHEP
reports. 2019;1(4):312-28.
Chitturi S, Abeygunasekera S, Farrell GC, Holmes-Walker
J, Hui JM, Fung C, et al. NASH and insulin resistance: insulin
hypersecretion and specific association with the insulin
resistance syndrome. 2002;35(2):373-9.
Vilar-Gomez E, Vuppalanchi R, Gawrieh S, Ghabril M,
Saxena R, Cummings OW, et al. Vitamin E improves
transplant-free survival and hepatic decompensation among
patients with nonalcoholic steatohepatitis and advanced
fibrosis. 2020;71(2):495-509.
Bril F, Biernacki DM, Kalavalapalli S, Lomonaco R,
Subbarayan SK, Lai J, et al. Role of vitamin E for nonalcoholic
steatohepatitis in patients with type 2 diabetes: a randomized
controlled trial. 2019;42(8):1481-8.
Goossens N, Isgro G, Negro FJCDoSR. Drugs improving
insulin resistance for non-alcoholic fatty liver disease and/or
non-alcoholic steatohepatitis. 2013(4).
Socha P, Horvath A, Vajro P, Dziechciarz P, Dhawan A,
Szajewska HJJopg, et al. Pharmacological interventions for
nonalcoholic fatty liver disease in adults and in children: a
systematic review. 2009;48(5):587-96.
Rakoski MO, Singal AG, Rogers MA, Conjeevaram HJAp,
therapeutics. Meta-analysis: insulin sensitizers for the treatment
of non-alcoholic steatohepatitis. 2010;32(10):1211-21.
clinic M. Empagliflozin And Linagliptin (Oral Route) 2022.
Available from: https://www.mayoclinic.org/drugssupplements/empagliflozin-and-linagliptin-oralroute/precautions/drg-20137736?p=1.
Tetri BA. Nonalcoholic Fatty Liver Disease (NAFLD) &
NASH: NIH; 2022. Available from: https://www.niddk.nih.
gov/health-information/liver-disease/nafld-nash.
Watada H, Yamauchi T, Yamamoto F, Taniguchi A, Yarush
L, Heilmann C, et al. Safety and tolerability of empagliflozin
and linagliptin combination therapy in patients with type 2
diabetes mellitus: a pooled analysis of data from five
randomized, controlled clinical trials. 2020;19(9):1193-202.
Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K,
Rinella M, et al. The diagnosis and management of
nonalcoholic fatty liver disease: practice guidance from the
American Association for the Study of Liver Diseases.
Hepatology (Baltimore, Md). 2018;67(1):328-57.
Blond E, Disse E, Cuerq C, Drai J, Valette P-J, Laville M, et
al. EASL–EASD–EASO clinical practice guidelines for the
management of non-alcoholic fatty liver disease in severely
obese people: do they lead to over-referral? Diabetologia.
;60:1218-22.
Cusi K. A diabetologist’s perspective of non-alcoholic
steatohepatitis (NASH): Knowledge gaps and future directions.
Liver International. 2020;40:82-8.
Smati S, Canivet CM, Boursier J, Cariou B. Anti-diabetic
drugs and NASH: from current options to promising
perspectives. Expert Opinion on Investigational Drugs.
;30(8):813-25.
Ranjbar G, Mikhailidis DP, Sahebkar A. Effects of newer
antidiabetic drugs on nonalcoholic fatty liver and
steatohepatitis: Think out of the box! Metabolism.
;101:154001.
Kothari S, Dhami-Shah H, Shah SR. Antidiabetic Drugs and
Statins in Nonalcoholic Fatty Liver Disease. Journal of Clinical
and Experimental Hepatology. 2019;9(6):723-30.
Kim KS, Lee BW. Beneficial effect of anti-diabetic drugs for
nonalcoholic fatty liver disease. Clinical and molecular
hepatology. 2020;26(4):430-43.
Athyros VG, Polyzos SA, Kountouras J, Katsiki N, Anagnostis
P, Doumas M, et al. Non-alcoholic fatty liver disease treatment
in patients with type 2 diabetes mellitus; new kids on the
block. 2020;18(2):172-81.
Jojima T, Tomotsune T, Iijima T, Akimoto K, Suzuki K, Aso
YJD, et al. Empagliflozin (an SGLT2 inhibitor), alone or in
combination with linagliptin (a DPP-4 inhibitor), prevents
steatohepatitis in a novel mouse model of non-alcoholic
steatohepatitis and diabetes. 2016;8(1):1-11.
Iogna Prat L, Tsochatzis EAJH. The effect of antidiabetic
medications on non-alcoholic fatty liver disease (NAFLD).
;17(2):219-29.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Asma Abdul Razzak, Pervez Ashraf
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Journal of Bahria University Medical & Dental College is an open access journal and is licensed under CC BY-NC 4.0. which permits unrestricted non commercial use, distribution and reproduction in any medium, provided the original work is properly cited. To view a copy of this license, visit https://creativecommons.org/licenses/by-nc/4.0 
